AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 05/09/19

The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more ...

Amneal Pharmaceuticals (NYSE: AMRX ): Q1 Non-GAAP EPS of $0.14 misses by $0.04 ; GAAP EPS of -$0.37. More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

‒ Q1 2019 Net Revenue of $446 Million; GAAP Loss per share of $0.37; Combined Adjusted Diluted EPS (1) of $0.14 ‒ ‒ Continued Progress in Diversifying Portfolio and Optimizing Business ‒ ‒ Reaffirming Full Year 2019 Financial Guidance ...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on Ma...

Skilled R&D leader brings more than two decades of generic and specialty experience – Led development of more than 200 products, including numerous first-to-file and first-to-market opportunities - Expertise in developing complex and difficult-to-formulate generics ...

BRIDGEWATER, N.J. , April 1, 2019 /PRNewswire/ --  Amneal Pharmaceuticals, Inc.   (NYSE: AMRX), today announced that it has entered into an agreement with Zentiva Group a.s., under which Zentiva has acquired Creo Pharmaceuticals Ltd., a subsidiary of Amneal that operates the co...

In a unanimous vote, the U.S. Federal Trade Commission (FTC) rules that Impax Laboratories LLC (NYSE: AMRX ) entered into an illegal pay-for-delay scheme with Endo Pharmaceuticals (NASDAQ: ENDP ) aimed at keeping the former's generic version of opioid pain med Opana ER (oxymorphone hydroch...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

BRIDGEWATER, N.J. , March 12, 2019 /PRNewswire/ --  Amneal Pharmaceuticals, Inc.   (NYSE: AMRX), today announced that it has launched its generic version of Exelon ® Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The Compa...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/14/2019. Please visit our Tracking Ole Andreas Halvorsen&#...